{"id":790314,"date":"2024-11-25T07:04:45","date_gmt":"2024-11-25T12:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-third-quarter-2024-financial-results-and-provides-business-update\/"},"modified":"2024-11-25T07:04:45","modified_gmt":"2024-11-25T12:04:45","slug":"nucana-reports-third-quarter-2024-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-third-quarter-2024-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Announced Promising Phase 1b\/2 Data on NUC-3373 in Combination with Pembrolizumab or Docetaxel<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Anticipated Cash Runway into Q2 2025<\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, Nov. 25, 2024 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

\u201cWe announced encouraging data from our ongoing clinical studies of both NUC-7738 and NUC-3373, underscoring the potential of our pipeline,\u201d said Hugh S. Griffith, NuCana\u2019s Founder and Chief Executive Officer. \u201cAt the European Society for Medical Oncology (ESMO) Congress 2024 in September, we presented promising data on NUC-7738, a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. The data from the Phase 2 part of the NuTide:701 study in PD-1 inhibitor-resistant melanoma showed that 9 of the 12 patients achieved disease control when treated with NUC-7738 in combination with pembrolizumab. One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume. Given the typically poor outcomes in this patient population, with a median progression-free survival of just two to three months under current standard care, we are highly encouraged by the results showing a median progression-free survival of over five months for patients receiving NUC-7738 plus pembrolizumab.\u201d<\/p>\n

Mr. Griffith added, \u201cWe also announced the issuance of a new patent by the United States Patent and Trademark Office covering NUC-7738\u2019s composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide.\u201d<\/p>\n

Mr. Griffith continued, \u201cWe recently announced initial data from the ongoing Phase 1b\/2 NuTide:303 study of NUC-3373, a targeted thymidylate synthase inhibitor with immune modulating properties, in a manuscript authored by the study\u2019s lead investigators. In this study, NUC-3373 is being combined with pembrolizumab in patients with advanced solid tumors and with docetaxel in patients with lung cancer. Results from the study indicate that NUC-3373 may promote an anti-tumor immune response and potentiate the activity of immune checkpoint inhibitors. We were particularly encouraged to see significant tumor volume reductions and prolonged progression free survival, including a patient with urothelial bladder cancer who achieved 100% reduction in their target lesions. While we were disappointed with the previously announced discontinuation of the NuTide:323 study in patients with metastatic colorectal cancer, we remain optimistic about the potential of NUC-3373.\u201d<\/p>\n

Mr. Griffith concluded, \u201cOur unwavering commitment to improving treatment outcomes for patients with cancer drives our relentless pursuit of the development of new anti-cancer agents. We look forward to progressing these exciting new medicines and sharing future development plans for NUC-7738 and NUC-3373.\u201d<\/p>\n

\n 2025 Anticipated Milestones<\/strong>\n <\/p>\n